Iyengar Capital Partners

Founder and Managing Director Tara Butler leads all investment decisions. She previously served as Senior Managing Director at Ascension Ventures, the strategic venture arm of Ascension Health, where she gained operational exposure to medical-device and life-sciences investing. Operating Partner Clayton Gentsch supports portfolio-company oversight.

The firm relies on a concentrated origination channel through serial entrepreneur Amar Sawhney and Incept LLC, the medical-device incubator Sawhney founded. Butler co-invests alongside Sawhney in companies spun out of Incept, including Rejoni and Sealonix. This model provides early access to surgeon-developed technologies before they reach broader venture syndicates.

Iyengar Capital focuses almost exclusively on early-stage investments, typically seed and Series A rounds. The firm's proximity to Incept LLC means it often commits capital before companies have full management teams or commercial traction, functioning as a first-institutional-check investor rather than a later-stage growth participant.

Public records indicate the firm makes direct equity investments rather than fund commitments. Its documented activity consists of direct co-investments alongside Amar Sawhney, Incept LLC, and Ascension Ventures. There is no evidence the firm allocates capital to outside venture funds.

The Iyengar Medical and Educational Foundation and the Shama Iyengar Mandayam Family Foundation are philanthropic entities associated with the principals' family. They appear to operate separately from the investment vehicle and are not known to hold portfolio-company equity or serve as deal-flow conduits.

The firm has not published formal sector exclusions, but its disclosed activity concentrates entirely on medical devices and adjacent life sciences. There are no verifiable investments in digital health, therapeutics, diagnostics, or health IT, suggesting a deliberate, narrow aperture rather than a generalist health mandate.

Altss classifies Iyengar Capital Partners as a single-family office, though it functions externally like a lean early-stage venture investor. The firm does not disclose outside limited partners, and its concentrated relationship with Amar Sawhney suggests proprietary capital deployment rather than institutional fund management.